Corticostriatal Circuit Dysfunction in Huntington's Disease: Intersection of Glutamate, Dopamine and Calcium

Overview

Journal Future Neurol

Specialty Neurology

Date 2011 Oct 7

PMID 21977007

Citations 41

Authors

Benjamin Ray Miller

Ilya Bezprozvanny

Affiliations

Soon will be listed here.

Abstract

Huntington's disease (HD) is a noncurable and progressive autosomal-dominant neurodegenerative disorder that results from a polyglutamine expansion in the amino-terminal region of the huntingtin protein. The generation of rodent HD models has revealed that cellular dysfunction, rather than cell death alone, occurs early in the disease progression, appearing even before overt symptom onset. Much evidence has now established that dysfunction of the corticostriatal circuit is key to HD symptomology. In this article, we summarize the most current findings that implicate glutamate, dopamine and calcium signaling in this system and discuss how they work in concert to disrupt corticostriatal function. In addition, we highlight therapeutic strategies related to altered corticostriatal signaling in HD.

Citing Articles

Advancements in Targeting Ion Channels for the Treatment of Neurodegenerative Diseases.

Li Y, Fu J, Wang H Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598374 PMC: 11597607. DOI: 10.3390/ph17111462.

Therapeutic approaches targeting aging and cellular senescence in Huntington's disease.

Bhat A, Moglad E, Afzal M, Thapa R, Almalki W, Kazmi I CNS Neurosci Ther. 2024; 30(10):e70053.

PMID: 39428700 PMC: 11491556. DOI: 10.1111/cns.70053.

The Complex Interplay between Toxic Hallmark Proteins, Calmodulin-Binding Proteins, Ion Channels, and Receptors Involved in Calcium Dyshomeostasis in Neurodegeneration.

ODay D Biomolecules. 2024; 14(2).

PMID: 38397410 PMC: 10886625. DOI: 10.3390/biom14020173.

Altered exocytosis of inhibitory synaptic vesicles at single presynaptic terminals of cultured striatal neurons in a knock-in mouse model of Huntington's disease.

Xu C, Chen S, Chen X, Ho K, Park C, Yoo H Front Mol Neurosci. 2023; 16:1175522.

PMID: 37664244 PMC: 10470468. DOI: 10.3389/fnmol.2023.1175522.

TRP channels: Role in neurodegenerative diseases and therapeutic targets.

Rather M, Khan A, Wang L, Jahan S, Rehman M, Makeen H Heliyon. 2023; 9(6):e16910.

PMID: 37332910 PMC: 10272313. DOI: 10.1016/j.heliyon.2023.e16910.

References

Papadia S, Hardingham G . The dichotomy of NMDA receptor signaling. Neuroscientist. 2007; 13(6):572-9. PMC: 2830536. DOI: 10.1177/10738584070130060401. View

Bachurin S, Shevtsova E, Kireeva E, Oxenkrug G, Sablin S . Mitochondria as a target for neurotoxins and neuroprotective agents. Ann N Y Acad Sci. 2003; 993:334-44; discussion 345-9. DOI: 10.1111/j.1749-6632.2003.tb07541.x. View

Hardingham G, Fukunaga Y, Bading H . Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci. 2002; 5(5):405-14. DOI: 10.1038/nn835. View

Cyr M, Beaulieu J, Laakso A, Sotnikova T, Yao W, Bohn L . Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons. Proc Natl Acad Sci U S A. 2003; 100(19):11035-40. PMC: 196922. DOI: 10.1073/pnas.1831768100. View

Albin R, Young A, Penney J . The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989; 12(10):366-75. DOI: 10.1016/0166-2236(89)90074-x. View

Kuczenski R, Segal D . Differential effects of amphetamine and dopamine uptake blockers (cocaine, nomifensine) on caudate and accumbens dialysate dopamine and 3-methoxytyramine. J Pharmacol Exp Ther. 1992; 262(3):1085-94. View

Beister A, Kraus P, Kuhn W, Dose M, Weindl A, Gerlach M . The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease. J Neural Transm Suppl. 2004; (68):117-22. DOI: 10.1007/978-3-7091-0579-5_14. View

Ehrnhoefer D, Butland S, Pouladi M, Hayden M . Mouse models of Huntington disease: variations on a theme. Dis Model Mech. 2009; 2(3-4):123-9. PMC: 2650190. DOI: 10.1242/dmm.002451. View

Wang H, Chen X, Li Y, Tang T, Bezprozvanny I . Tetrabenazine is neuroprotective in Huntington's disease mice. Mol Neurodegener. 2010; 5:18. PMC: 2873255. DOI: 10.1186/1750-1326-5-18. View

10.

Arzberger T, Krampfl K, Leimgruber S, Weindl A . Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington's disease--an in situ hybridization study. J Neuropathol Exp Neurol. 1997; 56(4):440-54. DOI: 10.1097/00005072-199704000-00013. View

11.

Bauer P, Nukina N . The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. J Neurochem. 2009; 110(6):1737-65. DOI: 10.1111/j.1471-4159.2009.06302.x. View

12.

Deng Y, Albin R, Penney J, Young A, Anderson K, Reiner A . Differential loss of striatal projection systems in Huntington's disease: a quantitative immunohistochemical study. J Chem Neuroanat. 2004; 27(3):143-64. DOI: 10.1016/j.jchemneu.2004.02.005. View

13.

Chang D, Rintoul G, Pandipati S, Reynolds I . Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons. Neurobiol Dis. 2006; 22(2):388-400. DOI: 10.1016/j.nbd.2005.12.007. View

14.

Rong R, Ahn J, Huang H, Nagata E, Kalman D, Kapp J . PI3 kinase enhancer-Homer complex couples mGluRI to PI3 kinase, preventing neuronal apoptosis. Nat Neurosci. 2003; 6(11):1153-61. DOI: 10.1038/nn1134. View

15.

Bibb J, Yan Z, Svenningsson P, Snyder G, Pieribone V, Horiuchi A . Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Proc Natl Acad Sci U S A. 2000; 97(12):6809-14. PMC: 18747. DOI: 10.1073/pnas.120166397. View

16.

Grigorev V, Dranyi O, Bachurin S . Comparative study of action mechanisms of dimebon and memantine on AMPA- and NMDA-subtypes glutamate receptors in rat cerebral neurons. Bull Exp Biol Med. 2004; 136(5):474-7. DOI: 10.1023/b:bebm.0000017097.75818.14. View

17.

Rymar V, Sasseville R, Luk K, Sadikot A . Neurogenesis and stereological morphometry of calretinin-immunoreactive GABAergic interneurons of the neostriatum. J Comp Neurol. 2004; 469(3):325-39. DOI: 10.1002/cne.11008. View

18.

Bezprozvanny I . Calcium signaling and neurodegenerative diseases. Trends Mol Med. 2009; 15(3):89-100. PMC: 3226745. DOI: 10.1016/j.molmed.2009.01.001. View

19.

Ondo W, Mejia N, Hunter C . A pilot study of the clinical efficacy and safety of memantine for Huntington's disease. Parkinsonism Relat Disord. 2006; 13(7):453-4. DOI: 10.1016/j.parkreldis.2006.08.005. View

20.

Pisani A, Bernardi G, Bonsi P, Centonze D, Giacomini P, Calabresi P . Cell-type specificity of mGluR activation in striatal neuronal subtypes. Amino Acids. 2000; 19(1):119-29. DOI: 10.1007/s007260070040. View